TY - JOUR
T1 - Burden of comorbid anxiety and depression in patients with inflammatory bowel disease
T2 - a systematic literature review
AU - Dubinsky, Marla C.
AU - Dotan, Iris
AU - Rubin, David T.
AU - Bernauer, Mark
AU - Patel, Dipen
AU - Cheung, Raymond
AU - Modesto, Irene
AU - Latymer, Mark
AU - Keefer, Laurie
N1 - Funding Information:
I Dotan has served on Advisory Boards/Speakers Bureau for Janssen, AbbVie, Takeda, Pfizer, Genentech/Roche, Neopharm, Celltrion, Rafa Laboratories, Ferring Pharmaceuticals Inc., Falk Pharma, MSD and Medtronic/Given Imaging; has received research funding from AbbVie, Pfizer and Altman Research; speaker or consultancy fees from Janssen, AbbVie, Takeda, Pfizer, Genentech/Roche, Arena, Neopharm, Gilead, Celltrion, Rafa Laboratories, Ferring, Falk Pharma, MSD, Protalix, Medtronic/Given Imaging, Medison, Sublimity Therapeutics and DSM.
Funding Information:
D T Rubin has received research funding from Takeda; has served as a consultant for AbbVie, AbGenomics, Allergan, Inc., Arena Pharmaceuticals, Biomica, Bristol-Myers Squibb, Dizal Pharmaceuticals, Ferring Pharmaceuticals Inc., Genentech/Roche, Janssen Pharmaceuticals, Lilly, Mahana Therapeutics, Medtronic, Merck & Co., Inc, Napo Pharmaceuticals, Pfizer, Prometheus Laboratories, Shire, Takeda, TARGET PharmaSolutions Inc, and is a co-founder of Cornerstones Health, Inc.
Funding Information:
M Dubinsky has received research funding from AbbVie, Janssen, Prometheus and Pfizer; has served as a consultant for AbbVie, Arena, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Janssen, Pfizer, Prometheus, Salix, Shire, Takeda and UCB; is a co-director of the Susan and Leonard Feinstein IBD Clinical Center, and is a co-founder of Mi-Test Health and Cornerstones Health, co-founder and shareholder of Trellus Health and Cornerstones Health.
Funding Information:
L Keefer has received research funding from AbbVie, served as a consultant to Pfizer and AbbVie, and is co-founder and shareholder of Trellus Health.
Publisher Copyright:
© 2021 Pfizer. Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Introduction: Patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, often have comorbid anxiety and depression that affects their quality of life (QoL) and management of their IBD. Areas covered: A systematic literature review (SLR) was conducted to identify articles and conference abstracts on comorbid anxiety and depression in IBD patients using MEDLINE® and Embase® (January 2003 − June 2018). The impact of these psychological comorbidities on QoL and economic burden was examined. Non-pharmacologic interventions and disease-specific unmet clinical needs associated with these comorbidities were also evaluated. Expert opinion: There is evidence that individual and group-based cognitive behavioral therapy can reduce rates of anxiety and depression in adults and adolescents with IBD. Patients with IBD and anxiety or depression had an increased risk of hospitalization, emergency department visits, readmission, and used outpatient services more often than people without these conditions. Several disease-specific unmet clinical needs for IBD patients were identified. These included lack of reimbursement for mental-health care, inconsistent screening for psychological comorbidities and patients not consulting mental-health professionals when needed. IBD patients may benefit from integrated medical and psychological treatment, and should be considered for behavioral treatment. Plain Language Summary Background: People with IBD may have mental-health conditions, such as anxiety and depression. These conditions can affect people’s quality of life and how they manage their IBD. What did this review look at?: We found 79 publications on anxiety or depression in people with IBD, published between January 2003 and June 2018. In people with IBD and anxiety or depression, researchers looked at: the impact on health-related quality of life and healthcare utilization, including access to and reimbursement for mental-health services how effective interventions that do not involve the use of medicines were (known as non-pharmacologic therapy). What were the main findings from this review?: People with IBD and anxiety or depression were more likely to be admitted to hospital and visit emergency departments than people without these conditions. Access to mental-health care varied and some people with IBD were not screened for depression. Individual and group-based talking therapy (known as cognitive behavioral therapy) reduced rates of anxiety and depression in some people with IBD. What were the main conclusions from this review?: We found evidence that people with IBD and anxiety or depression may benefit from certain non-pharmacologic interventions. However, many people with IBD and anxiety or depression did not have access to mental-health services. Healthcare professionals should address gaps in patient care to improve outcomes in people with IBD and anxiety or depression. See Additional file 1 for an infographic plain language summary.
AB - Introduction: Patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, often have comorbid anxiety and depression that affects their quality of life (QoL) and management of their IBD. Areas covered: A systematic literature review (SLR) was conducted to identify articles and conference abstracts on comorbid anxiety and depression in IBD patients using MEDLINE® and Embase® (January 2003 − June 2018). The impact of these psychological comorbidities on QoL and economic burden was examined. Non-pharmacologic interventions and disease-specific unmet clinical needs associated with these comorbidities were also evaluated. Expert opinion: There is evidence that individual and group-based cognitive behavioral therapy can reduce rates of anxiety and depression in adults and adolescents with IBD. Patients with IBD and anxiety or depression had an increased risk of hospitalization, emergency department visits, readmission, and used outpatient services more often than people without these conditions. Several disease-specific unmet clinical needs for IBD patients were identified. These included lack of reimbursement for mental-health care, inconsistent screening for psychological comorbidities and patients not consulting mental-health professionals when needed. IBD patients may benefit from integrated medical and psychological treatment, and should be considered for behavioral treatment. Plain Language Summary Background: People with IBD may have mental-health conditions, such as anxiety and depression. These conditions can affect people’s quality of life and how they manage their IBD. What did this review look at?: We found 79 publications on anxiety or depression in people with IBD, published between January 2003 and June 2018. In people with IBD and anxiety or depression, researchers looked at: the impact on health-related quality of life and healthcare utilization, including access to and reimbursement for mental-health services how effective interventions that do not involve the use of medicines were (known as non-pharmacologic therapy). What were the main findings from this review?: People with IBD and anxiety or depression were more likely to be admitted to hospital and visit emergency departments than people without these conditions. Access to mental-health care varied and some people with IBD were not screened for depression. Individual and group-based talking therapy (known as cognitive behavioral therapy) reduced rates of anxiety and depression in some people with IBD. What were the main conclusions from this review?: We found evidence that people with IBD and anxiety or depression may benefit from certain non-pharmacologic interventions. However, many people with IBD and anxiety or depression did not have access to mental-health services. Healthcare professionals should address gaps in patient care to improve outcomes in people with IBD and anxiety or depression. See Additional file 1 for an infographic plain language summary.
KW - Anxiety
KW - Crohn’s disease
KW - cognitive behavioral therapy
KW - depression
KW - inflammatory bowel disease
KW - psychological comorbidity
KW - quality of life
KW - systematic literature review
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85108004737&partnerID=8YFLogxK
U2 - 10.1080/17474124.2021.1911644
DO - 10.1080/17474124.2021.1911644
M3 - Review article
C2 - 34130572
AN - SCOPUS:85108004737
SN - 1747-4124
VL - 15
SP - 985
EP - 997
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
IS - 9
ER -